163 related articles for article (PubMed ID: 10954015)
1. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats.
Adachi T; Yasuda K; Okamoto Y; Shihara N; Oku A; Ueta K; Kitamura K; Saito A; Iwakura I; Yamada Y; Yano H; Seino Y; Tsuda K
Metabolism; 2000 Aug; 49(8):990-5. PubMed ID: 10954015
[TBL] [Abstract][Full Text] [Related]
2. Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats.
Oku A; Ueta K; Arakawa K; Kano-Ishihara T; Matsumoto M; Adachi T; Yasuda K; Tsuda K; Saito A
Biol Pharm Bull; 2000 Dec; 23(12):1434-7. PubMed ID: 11145172
[TBL] [Abstract][Full Text] [Related]
3. Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats.
Oku A; Ueta K; Nawano M; Arakawa K; Kano-Ishihara T; Matsumoto M; Saito A; Tsujihara K; Anai M; Asano T
Eur J Pharmacol; 2000 Mar; 391(1-2):183-92. PubMed ID: 10720650
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746
[TBL] [Abstract][Full Text] [Related]
5. Normalization of cytoplasmic calcium response in pancreatic beta-cells of spontaneously diabetic GK rat by the treatment with T-1095, a specific inhibitor of renal Na+-glucose co-transporters.
Yasuda K; Okamoto Y; Nunoi K; Adachi T; Shihara N; Tamon A; Suzuki N; Mukai E; Fujimoto S; Oku A; Tsuda K; Seino Y
Horm Metab Res; 2002 Apr; 34(4):217-21. PubMed ID: 11987033
[TBL] [Abstract][Full Text] [Related]
6. Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats.
Oku A; Ueta K; Arakawa K; Kano-Ishihara T; Matsumoto T; Adachi T; Yasuda K; Tsuda K; Ikezawa K; Saito A
Jpn J Pharmacol; 2000 Nov; 84(3):351-4. PubMed ID: 11138738
[TBL] [Abstract][Full Text] [Related]
7. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
Oku A; Ueta K; Arakawa K; Ishihara T; Nawano M; Kuronuma Y; Matsumoto M; Saito A; Tsujihara K; Anai M; Asano T; Kanai Y; Endou H
Diabetes; 1999 Sep; 48(9):1794-800. PubMed ID: 10480610
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
[TBL] [Abstract][Full Text] [Related]
9. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
10. Ameliorative effect of polydatin on hyperglycemia and renal injury in streptozotocin-induced diabetic rats.
Wang L; Huang L; Li N; Miao J; Liu W; Yu J
Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):55-59. PubMed ID: 31880518
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
12. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.
Vallon V; Rose M; Gerasimova M; Satriano J; Platt KA; Koepsell H; Cunard R; Sharma K; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2013 Jan; 304(2):F156-67. PubMed ID: 23152292
[TBL] [Abstract][Full Text] [Related]
13. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y
Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232
[TBL] [Abstract][Full Text] [Related]
14. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Liang Y; Arakawa K; Ueta K; Matsushita Y; Kuriyama C; Martin T; Du F; Liu Y; Xu J; Conway B; Conway J; Polidori D; Ways K; Demarest K
PLoS One; 2012; 7(2):e30555. PubMed ID: 22355316
[TBL] [Abstract][Full Text] [Related]
15. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
Fujimori Y; Katsuno K; Ojima K; Nakashima I; Nakano S; Ishikawa-Takemura Y; Kusama H; Isaji M
Eur J Pharmacol; 2009 May; 609(1-3):148-54. PubMed ID: 19281809
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats.
Nunoi K; Yasuda K; Adachi T; Okamoto Y; Shihara N; Uno M; Tamon A; Suzuki N; Oku A; Tsuda K
Clin Exp Pharmacol Physiol; 2002; 29(5-6):386-90. PubMed ID: 12010180
[TBL] [Abstract][Full Text] [Related]
17. Effects of Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) on hyperglycemia in streptozotocin-induced diabetic rats.
Hirotani Y; Ikeda T; Yamamoto K; Kurokawa N
Biol Pharm Bull; 2007 May; 30(5):1015-20. PubMed ID: 17473455
[TBL] [Abstract][Full Text] [Related]
18. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats.
Ueta K; Ishihara T; Matsumoto Y; Oku A; Nawano M; Fujita T; Saito A; Arakawa K
Life Sci; 2005 Apr; 76(23):2655-68. PubMed ID: 15792833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
